Why is Glenmark Pharma falling/rising?

As of 01-Aug, Glenmark Pharmaceuticals Ltd. is experiencing a decline in its stock price, currently at Rs 2,083.50, reflecting a decrease of Rs 49.7 or 2.33%. The stock has been on a downward trend for the past three days, with a total drop of 3.52% during this period. Today's performance indicates that it has outperformed its sector by 0.83%, despite the overall negative movement. The stock's recent returns show a 1-week decline of 2.64%, while it has performed well over the longer term, with a 1-month increase of 18.76% and a year-to-date rise of 29.50%. Positive factors include strong financial performance, with a 576.7% growth in PAT over the last four quarters and a low Debt to EBITDA ratio, which suggests a strong ability to service debt. However, the stock's recent price decline may be influenced by falling investor participation, as evidenced by a 16.86% drop in delivery volume compared to the 5-day average.
Broader market context indicates that Glenmark's short-term performance has been weaker than the benchmark, with the Sensex showing a decline of only 1.06% over the same 1-week period. The pharmaceuticals and drugs sector has also faced challenges, falling by 3.26%. Despite Glenmark's strong historical returns, including a 44.85% increase over the past year, the current market conditions and sector performance may be contributing to the stock's recent decline. The high institutional holdings at 38.3% suggest that informed investors are still backing the company, but the recent drop in trading volume and sector-wide weakness could be impacting market sentiment negatively.